Cantor Fitzgerald Initiates StemCells With Buy

Analysts at Cantor Fitzgerald initiated coverage on StemCells Inc STEM with a Buy rating. The target price for StemCells is set to $2. StemCells shares have dropped 56.43 percent over the past 52 weeks, while the S&P 500 index has surged 12.12 percent in the same period. StemCells' shares rose 4.21 percent to $0.639 in after-hours trading.